HIV continues to affect the health and wellbeing of people in Europe. In 2020, 14,971 new HIV diagnoses were reported in 29 countries of the EU/EEA. This video explain how we can reduce these numbers
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-24 July 2021 and includes updates on Escherichia coli ST38, COVID-19, Vibrio growth in the Baltic Sea the Olympic Games in Tokyo 2020 (2021), West Nile virus, avian influenza and cholera.
Supplementary document with country case studies in relation to the ECDC operational guidance on HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: Implementation, standards and monitoring.
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
ECDC has developed an operational guidance to support countries in their efforts and to harmonise the overall approach taken to PrEP implementation in the region.
One of the targets of the Sustainable Development Goals is to end the AIDS epidemic by 2030. Still, 2 094 AIDS cases were reported in the EU/EEA during 2019. This shows a significant problem with late diagnosis of HIV infection. Detecting HIV only years after the infection is one reason for on-going transmission in Europe. One in every four AIDS cases occurred long after HIV diagnosis, indicating insufficient linkage to HIV care, access to antiretroviral treatment and adherence support.
Depending on the level of evidence provided and the methodology used, this advice is typically conveyed through a Guidance, a Systematic review or an Expert opinion.
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.